In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helen of Troy Q3

This article was originally published in The Rose Sheet

Executive Summary

Sales for company's personal-care unit decreased 6.2% to $162.99 mil. in the fiscal 2008 third quarter and slipped 0.4% to $388.3 mil. over the nine months ended Nov. 30, 2007, compared with the prior-year periods. "Our Personal Care segment is facing a challenging sales environment, which we anticipate will continue through at least the first half of this calendar year," CEO Gerald J. Rubin says, adding: "We are in the process of shifting the Belson sourcing to our current suppliers, which we expect to provide margin improvement opportunities sometime in fiscal year 2009." Helen of Troy acquired Belson Products in spring 2007; it was formerly the professional salon division of Applica Consumer Products ("The Rose Sheet" May 14, 2007, In Brief). Company also aims to expand sales and distribution of its Bed Head by TIGI line and to "reevaluate [its] Personal Care segment's domestic product line mix, and its selling, branding and production forecasting operations," according to Jan. 9 release. Like it did last quarter, firm is revising its full-year guidance, projecting sales in the range of $645 mil. to $655 mil. versus $660 to $680, and earnings of $1.85 to $1.95 per fully diluted share versus $1.90 to $2.10 ("The Rose Sheet" Oct. 22, 2007, p. 8). Earnings for Q3 and the nine-month period were $22.84 mil., or $0.73 per fully diluted share, and $51.21 mil., or $1.60 per diluted share, respectively...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel